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We report a novel parvovirus (PARV4) and related
variants in pooled human plasma used in the manufacture
of plasma-derived medical products. Viral DNA was detect-
ed by using highly selective polymerase chain reaction
assays; 5% of pools tested positive, and amounts of DNA
ranged from <500 copies/mL to >106 copies/mL plasma.
U
sing a sequence-independent polymerase chain reac-
tion (PCR) amplification method, we recently identi-
fied a new parvovirus in plasma from a patient with
exposures and symptoms consistent with acute HIV infec-
tion, but who was HIV RNA negative (1). Phylogenetic
analyses of sequence data suggest that this virus, termed
PARV4, is only distantly related to previously known
human or animal members of the family Parvoviridae,
including members of the Erythrovirus genus known to
infect humans, such as parvovirus B19. Infection with par-
vovirus B19, although frequently asymptomatic, may
result in erythema infectiosum, arthropathy, pregnancy
complications (e.g., hydrops fetalis), transient aplastic cri-
sis, and disease in immunocompromised patients (2).
Parvovirus B19 is most frequently transmitted through the
respiratory route or vertically from mother to fetus.
However, blood- and plasma-derived medical products,
particularly clotting factors, contaminated with parvovirus
B19 can also transmit the virus (3). Manufacturers of plas-
ma derivatives screen minipools by using nucleic acid
amplification techniques (NAT), which has enabled levels
of erythrovirus DNA to be substantially reduced in start
pools; for certain products, screening is now a regulatory
requirement (4). This study examined pooled human plas-
ma for fractionation to detect PARV4 DNA sequences.
The Study
Samples of manufacturing plasma pools submitted to
the National Institute for Biological Standards and Control
for testing for hepatitis C virus RNA were stored at –70°C
until analysis, in compliance with European regulatory
requirements. Manufacturing pools were sourced from
donations collected in Europe and North America and
received during the previous 6 months. Total nucleic acid
was extracted from plasma pools as described previously
(4) before analysis for PARV4 DNA.
Using multiple sequence alignments of human ery-
throviruses and comparison with the sequence for PARV4
(1), we designed highly selective primers to the open read-
ing frame 1 (ORF1) of PARV4, homologous to the non-
structural proteins of other parvoviruses. Primers
PV4ORF1F (5′-AAGACTACATACCTACCTGTG-3′) and
PV4ORF1R (5′-GTGCCTTTCATATTCAGTTCC-3′)
amplify a 220-bp region of ORF1. The specificity of these
primers was confirmed by PCR using a cloned fragment of
the ORF1 region alongside erythrovirus control material
(Figure 1A). Each PCR contained 1× PCR buffer II (PE
Applied Biosystems, Warrington, UK), 200 µmol/L each
deoxynucleoside triphosphate, 2 mmol/L MgCl2, 10 pmol
each primer, and 2.5 U AmpliTaq Gold DNA polymerase
(PE Applied Biosystems) in a final volume of 50 µL. For
thermal cycling, a T3 thermal cycler (Biometra, Göttingen,
Germany) was used with the following cycling conditions:
95°C for 9 min, followed by 45 cycles of 96°C for 30 s,
55°C for 30 s, and 72°C for 1 min. Amplicons were ana-
lyzed by agarose gel electrophoresis and compared to
known size markers. The PARV4 control sequences
(nucleotides 1293–1833 of ORF1, GenBank accession no.
AY622943) were cloned into the vector pT7 Blue accord-
ing to the manufacturer’s instructions (Novagen,
Darmstadt, Germany). The sensitivity of these PCR reac-
tions was 1–10 copies of PARV4 sequences. DNA extract-
ed from 137 pools was screened for PARV4 ORF1
sequences by PCR using 5 µL extracted DNA. Results,
summarized in Table 1, show that 7 of 137 plasma pools
screened with these primers tested positive for PARV4
DNA sequences and those of a related variant, known as
PARV5. Typical results from pools and control plasmid
samples are shown in Figure 1B. DNA sequence analysis
showed that PARV5, over the region amplified, shares
≈92% nucleotide identity with PARV4 (Figure 2). Further
sequence analysis around the primer-binding sites showed
that the primers were 100% homologous in both geno-
types. This level of relatedness is similar to that seen for
the different erythrovirus genotypes (7).
The levels of PARV4 in the positive plasma pools were
determined by real-time PCR using the screening primers
from the ORF1 region of PARV4. Amplification reactions
were performed on the LightCycler instrument using the
LightCycler FastStart DNA MasterPLUS SYBR green I kit
(Roche Applied Science, Mannheim, Germany) in accor-
dance with the manufacturers’ instructions. A standard
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taining the ORF1 fragment of PARV4. Levels of PARV4
DNA were as high as 3.9 × 106 copies/mL plasma,
although several pools contained <500 copies/mL plasma
(Table 2).
Plasma pools found positive for PARV4 sequences
were tested for the levels of erythrovirus DNAas described
previously (4). Only 2 of the PARV4-positive pools con-
tained any human erythrovirus DNA, and these were at
low levels (Table 2). Of the plasma pools found to be pos-
itive for PARV4 sequences, blood products from only 2
were available for further analysis. Both products were
immunoglobulin preparations, and in neither case could
PARV4 sequences be detected.
Conclusions
This report is the first to describe novel parvovirus
sequences in pooled human plasma for fractionation.
PARV4 was originally identified in a patient with acute
viral infection syndrome coinfected with hepatitis B virus
(1). As yet, nothing is known about the prevalence of
PARV4, its possible role in human disease, or whether
PARV4 was transmitted to the original patient from an
unidentified animal host.
Although PARV4 shares limited homology with human
erythroviruses, the latter are frequent contaminants of plas-
ma, pooled and used for fractionation (3). Levels of PARV4
DNA ranged from <500 copies/mL to >106 copies/mL
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Figure 1. A) Specificity of primers for PARV4. Samples in lanes
1–5 were amplified by using primers directed to open reading
frame 1 (ORF1) of PARV4. Template DNA in lane 1 was a plasmid
subclone of the PARV4 ORF1 region. In lane 2, the template DNA
was derived from parvovirus B19 International Standard (99/800,
National Institute for Biological Standards and Control, South
Mimms, UK) as representative of genotype 1 erythrovirus
sequences; in lane 3, the template DNA was derived from a geno-
type 2 erythrovirus plasmid clone (A6; obtained from K. Brown,
National Heart, Lung and Blood Institute, Bethesda, MD, USA); in
lane 4, the template DNA was derived from a genotype 3 ery-
throvirus plasmid clone (D91.1; obtained from A. Garbarg-Chenon,
Hôpital Trousseau, Paris, France). Template DNA in the ery-
throvirus samples (lanes 2–4) was adjusted to give ≈105.5 copies
of each genotype per reaction. Lane 5, no template control.
Polymerase chain reaction (PCR) products were analyzed on a
2.5% agarose gel alongside PCR Markers (M) (Promega,
Madison, WI, USA). B) Screening manufacturing plasma samples
for PARV4. Samples in lanes 1–6 were amplified by using primers
directed to the ORF1 region of PARV4. Template DNA in lanes 1
and 2 consisted of 1 × 102 and 1 × 103 copies of the ORF1 sub-
clone of PARV4. In lane 3, the template DNA was derived from a
plasma pool containing 3.9 × 106 PARV4 genome copies/mL plas-
ma; in lane 4, the template DNA was derived from a plasma pool
containing <500 PARV4 genome copies/mL plasma; in lane 5, the
template DNA was derived from a plasma pool that tested nega-
tive for PARV4 sequences. Lane 6, no template control. PCR prod-
ucts were analyzed on a 2.5% agarose gel alongside PCR
Markers (M) (Promega).
Figure 2. Phylogenetic analysis of a 178-bp sequence of ORF1 of
PARV4 and PARV5 (GenBank accession no. DQ112361) with
other members of the Parvoviridae subfamily. The alignment
includes the members of the Erythrovirus genus (parvovirus B19
[5]) and related viruses such as V9 (6), D91.1 (7), and A6 (8), as
well as the closely related viruses infecting the cynomolgus
macaque (LTMPV) (9) and rhesus (RMPV) and pig-tailed
macaques (PTMPV) (10). Two other viruses tentatively assigned
to the group include a parvovirus isolated from chipmunks (11);
BPV3, a novel bovine parvovirus (BPV3) (12); and porcine par-
vovirus 2 (PPV2) (13). Analysis was performed by using the pro-
gram ClustalW (14).plasma. If a single donation with a high PARV4 count was
responsible for the contamination of such a pool, the lev-
els of virus DNAin the original donation would have been
in the order of 109 or 1010 copies/mLplasma, given the vol-
ume of the start pool. Because erythroviruses are small,
nonenveloped, and relatively resistant to virus inactivation
procedures, manufacturers of plasma-derived products
have used NAT to exclude high-titer donations from man-
ufacturing start pools. Before such measures were intro-
duced, more than half of production start pools contained
erythrovirus DNA, some with titers of 109 copies/mL plas-
ma (4; S. Baylis, unpub. data). The prevalence of PARV4
and PARV5 and the titers observed in the pools examined
in this study are much lower than the usual prevalence and
titers observed with erythroviruses. Because of PARV4’s
insufficient homology with human erythroviruses, current
methods of NAT are unlikely to identify donations positive
for PARV4.
The availability of highly specific reagents for PARV4
and PARV5 will assist in further studies to elucidate their
possible role in human disease. The detection of PARV4
and PARV5 in plasma may have been caused by an epi-
demic at the time of plasma donation. In a recent study that
screened for enteroviruses in human plasma, seasonal
changes were observed in the frequency and level of
viremia (15). Studies to examine the epidemiology of
PARV4 and PARV5 infection will help address issues such
as these.
In summary, PARV4, a novel parvovirus, and PARV5, a
related variant, have been identified in plasma used in the
manufacture of blood products. Plasma is obtained from
healthy persons, who at the time of donation are asympto-
matic, despite being viremic for PARV4 or PARV5. Highly
specific and sensitive assays to detect PARV4 will facili-
tate further analysis of the role of this novel virus in human
disease and the implications of virus transmission by con-
taminated blood and blood products.
Note
After this article was submitted for publication, human
bocavirus, a novel parvovirus, was identified in respiratory tract
samples (16). PARV4 and PARV5 are distinct from human
bocavirus. For example, comparison of PARV4 (AY622943) with
human bocavirus strains ST and ST2 (DQ000495 and
DQ000496) shows nucleotide identity of 41% and 40%, respec-
tively.
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